NO20052952L - Farmasoytisk sammensetning som innbefatter mikropartikler - Google Patents

Farmasoytisk sammensetning som innbefatter mikropartikler

Info

Publication number
NO20052952L
NO20052952L NO20052952A NO20052952A NO20052952L NO 20052952 L NO20052952 L NO 20052952L NO 20052952 A NO20052952 A NO 20052952A NO 20052952 A NO20052952 A NO 20052952A NO 20052952 L NO20052952 L NO 20052952L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
microparticles
polymer
glycolide
lactide
Prior art date
Application number
NO20052952A
Other languages
English (en)
Other versions
NO20052952D0 (no
Inventor
Jean-Daniel Bonny
Michael Ausborn
Holger Petersen
Rolf Lofler
Olivier Lambert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32299717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052952(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0226993A external-priority patent/GB0226993D0/en
Priority claimed from GB0227883A external-priority patent/GB0227883D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20052952D0 publication Critical patent/NO20052952D0/no
Publication of NO20052952L publication Critical patent/NO20052952L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Det beskrives et farmasøytisk preparat omfattende octreotidacetat mikropartikler av lineær poly (laktid-ko-glykolid) polymer der polymeren inneholder mindre enn I % silikonolje eller heptan.
NO20052952A 2002-11-19 2005-06-16 Farmasoytisk sammensetning som innbefatter mikropartikler NO20052952L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0226993A GB0226993D0 (en) 2002-11-19 2002-11-19 Organic compounds
GB0227883A GB0227883D0 (en) 2002-11-29 2002-11-29 Organic compounds
PCT/EP2003/012898 WO2004045633A2 (en) 2002-11-19 2003-11-18 Pharmaceutical composition comprising octreotide microparticles

Publications (2)

Publication Number Publication Date
NO20052952D0 NO20052952D0 (no) 2005-06-16
NO20052952L true NO20052952L (no) 2005-08-15

Family

ID=32299717

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052952A NO20052952L (no) 2002-11-19 2005-06-16 Farmasoytisk sammensetning som innbefatter mikropartikler

Country Status (16)

Country Link
US (6) US20040097419A1 (no)
EP (2) EP1565161A2 (no)
JP (2) JP2006514927A (no)
KR (2) KR101240071B1 (no)
AU (3) AU2003293700A1 (no)
BR (1) BR0316421A (no)
CA (1) CA2501978C (no)
CO (1) CO5690533A2 (no)
EC (1) ECSP055800A (no)
ES (1) ES2577613T3 (no)
MX (1) MXPA05005388A (no)
NO (1) NO20052952L (no)
PL (1) PL376015A1 (no)
PT (1) PT2377519E (no)
RU (2) RU2404748C2 (no)
WO (1) WO2004045633A2 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062652B2 (en) 2004-06-17 2011-11-22 Endo Pharmaceuticals Solutions Inc. Compositions and methods for treating precocious puberty
DE602005013244D1 (de) * 2004-08-12 2009-04-23 Quest Pharmaceutical Services Pharmazeutische zusammensetzungen für die kontroll
JP2008524235A (ja) * 2004-12-15 2008-07-10 キューエルティー ユーエスエー，インコーポレイテッド． オクトレオチド化合物の徐放性送達処方物
CN101193626A (zh) * 2005-03-11 2008-06-04 益德威士医药股份有限公司 奥曲肽的受控释放制剂
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
ES2383303T3 (es) 2005-11-10 2012-06-20 Chemi S.P.A. Formulaciones de inhibidores de la liberación prolongada de la hormona del crecimiento análogos de la somatostatina
ES2755032T3 (es) * 2005-12-22 2020-04-21 Novartis Ag Formulación de liberación sostenida que comprende octreótido y dos o más polímeros de poliláctido-co-glicólido
KR100722607B1 (ko) 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
CA2685397C (en) * 2007-04-27 2016-07-26 Endo Pharmaceuticals Solutions Inc. Implant device release agents and methods of using same
CA2729139C (en) * 2008-06-25 2016-07-26 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
EP2303226B1 (en) * 2008-06-25 2016-03-23 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
KR101814186B1 (ko) 2008-09-17 2018-03-14 키아스마 인코포레이티드 약제학적 조성물 및 연관된 투여방법
JP5769626B2 (ja) 2008-09-18 2015-08-26 エボニック コーポレイションＥｖｏｎｉｋ Ｃｏｒｐｏｒａｔｉｏｎ 溶媒および塩を用いるマイクロカプセル封入プロセス
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
CN115957297A (zh) 2013-03-15 2023-04-14 节奏制药公司 药物组合物
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
CN106727448B (zh) * 2016-12-12 2020-10-13 广州中大南沙科技创新产业园有限公司 醋酸奥曲肽干粉吸入制剂及其制备方法
ES3002659T3 (en) 2017-02-27 2025-03-07 Univ Of Pittsburgh Of The Commonwealthsystem Of Higher Education Anti-psychotic composition and treatment methods
WO2019155396A1 (en) * 2018-02-07 2019-08-15 Dr. Reddy's Laboratories Limited Sustained release microspheres with low initial burst and methods of preparation thereof
KR101936040B1 (ko) 2018-04-23 2019-01-08 주식회사 씨트리 안정화된 단상 혼합액을 이용하는 생분해성 미립구의 제조방법
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE3062075D1 (en) 1979-11-27 1983-03-24 Sandoz Ag Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use
DE3032345C2 (de) * 1980-08-28 1984-06-28 Mathias 4815 Schloss Holte Mitter Lagerung einer Rakel mit seitlich außerhalb der Schablone eines Siebdruckwerkes angeordneten Lagern
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
DK0471036T4 (da) * 1989-05-04 2004-07-19 Southern Res Inst Indkapslingsfremgangsmåde
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
MY108621A (en) * 1990-08-01 1996-10-31 Novartis Ag Polylactide preparation and purification
US6353030B1 (en) * 1990-08-01 2002-03-05 Novartis Ag Relating to organic compounds
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
GB9805417D0 (en) * 1998-03-14 1998-05-06 Core Technologies Limited Production of microparticles
FR2778100B1 (fr) * 1998-04-29 2001-05-04 Virsol Nouvelles microspheres a base de poly(methylidene malonate), leur procede de preparation et compositions pharmaceutiques les contenant
US6204308B1 (en) * 1999-03-01 2001-03-20 Novartis Ag Organic compounds
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
WO2002049620A2 (en) * 2000-12-21 2002-06-27 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophobic active agents

Also Published As

Publication number Publication date
US20220273574A1 (en) 2022-09-01
PT2377519E (pt) 2016-06-09
AU2008200018B2 (en) 2010-12-09
EP2377519A3 (en) 2011-11-23
KR20050086708A (ko) 2005-08-30
RU2404748C2 (ru) 2010-11-27
NO20052952D0 (no) 2005-06-16
AU2011200966A1 (en) 2011-03-24
ES2577613T3 (es) 2016-07-15
AU2003293700A1 (en) 2004-06-15
EP1565161A2 (en) 2005-08-24
RU2005119632A (ru) 2006-05-10
EP2377519B1 (en) 2016-03-23
CO5690533A2 (es) 2006-10-31
US20070122485A1 (en) 2007-05-31
JP2006514927A (ja) 2006-05-18
WO2004045633A3 (en) 2005-01-13
KR20120032537A (ko) 2012-04-05
US20140323415A1 (en) 2014-10-30
CA2501978C (en) 2013-12-17
WO2004045633A2 (en) 2004-06-03
JP2011256185A (ja) 2011-12-22
BR0316421A (pt) 2005-10-11
RU2010144614A (ru) 2012-05-10
JP5784402B2 (ja) 2015-09-24
US20170281548A1 (en) 2017-10-05
AU2011200966B2 (en) 2013-08-01
EP2377519A2 (en) 2011-10-19
MXPA05005388A (es) 2005-08-03
CA2501978A1 (en) 2004-06-03
US20200009056A1 (en) 2020-01-09
KR101240071B1 (ko) 2013-03-06
PL376015A1 (en) 2005-12-12
AU2008200018A1 (en) 2008-01-31
HK1161123A1 (en) 2012-08-24
US20040097419A1 (en) 2004-05-20
KR101146471B1 (ko) 2012-05-21
ECSP055800A (es) 2005-08-11

Similar Documents

Publication Publication Date Title
NO20052952L (no) Farmasoytisk sammensetning som innbefatter mikropartikler
BRPI0514630B8 (pt) compostos de alfa-mercaptoacetanilidas de s-triazolila e composições farmacêuticas
BRPI0407882A (pt) conjugados de polìmero-porção de fator viii
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
WO2003106582A8 (fr) Adhesif pour sceller un element electroluminescent organique et son utilisation
DE60334401D1 (de) Orale darreichungsform mit flüssigen hochviskosen trägersystemen
EP1518601A4 (en) PHOTO CATALYST COMPOSITION
ATE241341T1 (de) Stabilisierte pharmazeutische zusammensetzung
DE60302396D1 (de) Verfharen zur Herstellung von Wärmedämmschicht mit Nitridpartikeln
DE60214853D1 (de) Biologisch abbaubare kaugummigrundmasse
DK1606339T3 (da) Polymer film eller belægning omfattende hemicellulose
AR035120A1 (es) Proceso para producir poliester con dioxido de titanio recubierto
JP2006506311A5 (no)
EA200001201A2 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
DE60308508D1 (de) Extrudierbare thermoplastische zusammensetzungen
NO20020006L (no) Sammensetninger omfattende organosiloksanresiner for levering av oral-pleie substanser
DE60200719D1 (de) Filmbildende Zusammensetzung, poröser Film und deren Herstellung
BR0109369A (pt) Composição formadora de pelìcula curável, artigo revestido, e método para preparar um substrato revestido
BR0012122A (pt) Composições compreendendo resinas de organosiloxano para liberação de substâncias de cuidados orais
DE50203760D1 (de) Pla-folie mit guten antistatischen eigenschaften
AR032642A1 (es) Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponibilidad oral.
NO20054945D0 (no) Orale formulering av cladribin
BR0008933A (pt) Composição para vela
BR0318237A (pt) sonda vascular
ATE364321T1 (de) Kaugummigrundlage und kaugummi mit sehr hochmolekularem polyvinylacetat

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application